Document Type

Fact Sheet

Publication Date



Nearly a third of Kenya’s 51 million people live in malaria-endemic zones and pregnant women are especially susceptible to malaria infection. Intermittent preventive treatment of malaria in pregnancy (IPTp) using sulfadoxine-pyrimethamine (SP) helps prevent maternal malaria episodes, maternal and fetal anemia, placental parasitemia, low birth-weight, and neonatal mortality. WHO’s guidelines on IPTp recommend that pregnant women living in moderate to high malaria transmission areas in sub-Saharan Africa receive a dose of SP at each antenatal care visit, beginning in the second trimester. IPTp-SP is recommended alongside insecticide-treated nets and appropriate case management. Kenya adopted WHO’s recommendations in 1998, however IPTp-SP uptake by pregnant women remains low. As stated in this fact sheet, the Population Council-Kenya is leading the 2020-2025 REVIVE IPTp-SP project, which seeks to contribute to the government of Kenya’s national target of 80% coverage of IPTp-SP for MiP by 2025. The project is implementing interventions to increase IPTp-SP coverage in two high-prevalence malaria-endemic counties in Kenya, Migori and Kisumu, through: policy clarification and consensus building, capacity building and strengthening, promoting user empowerment and self-care for the communities and pregnant mothers, and Improving monitoring, evaluation, and shared learning.






Revive IPTp-SP: Revitalization of Intermittent Preventive Treatment of Malaria in Pregnancy